Neuropeptide Y (NPY) prevents depressive-like behavior, Spatial memory deficits and oxidative stress following amyloid-β (Aβ1-40) administration in mice

Behavioural Brain Research

Volumn 244, Issue , 2013, Pages 107-115

  dos Santos, Vanessa V ^a   Santos, Danúbia B ^a   Lach, Gilliard ^a   Rodrigues, Ana Lúcia S ^a   Farina, Marcelo ^a   De Lima, Thereza C M ^a   Prediger, Rui Daniel ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Alzheimer's disease; Amyloid protein; Depression; Glutathione; Mice; Neuropeptide Y (NPY); Oxidative stress; Spatial memory

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; GLUTATHIONE; GLUTATHIONE PEROXIDASE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; HIPPOCAMPUS; LIPID PEROXIDATION; LOCOMOTION; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SPATIAL MEMORY; TASK PERFORMANCE;

AMYLOID BETA-PEPTIDES; ANIMALS; ARGININE; BENZAZEPINES; CEREBRAL CORTEX; DEPRESSION; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; LIPID PEROXIDATION; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MOTOR ACTIVITY; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RECEPTORS, NEUROPEPTIDE Y;

EID: 84874546424     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.01.039     Document Type: Article

References (75)

1. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rossor M.N., Roberts G.W., et al. Neuropeptide Y distribution in human brain. Nature 1983, 306:584-586.
2. Stanley B.G., Leibowitz S.F. Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sciences 1984, 35:2635-2642.
3. Flood J.F., Hernandez E.N., Morley J.E. Modulation of memory processing by neuropeptide Y. Brain Research 1987, 421:280-290.
4. Cleary J., Semotuk M., Levine A.S. Effects of neuropeptide Y on short-term memory. Brain Research 1994, 653:210-214.
5. Redrobe J.P., Dumont Y., St-Pierre J.A., Quirion R. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Research 1999, 848:153-166.
6. Colmers W.F., Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends in Neurosciences 1994, 17:373-379.
7. Woldbye D.P., Madsen T.M., Larsen P.J., Mikkelsen J.D., Bolwig T.G. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Research 1996, 737:162-168.
8. Vezzani A., Sperk G., Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends in Neurosciences 1999, 22:25-30.
9. Heilig M., Wahlestedt C., Ekman R., Widerlov E. Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. European Journal of Pharmacology 1988, 147:465-467.
10. Redrobe J.P., Dumont Y., Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sciences 2002, 71:2921-2937.
11. Husum H., Mikkelsen J.D., Hogg S., Mathe A.A., Mork A. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000, 39:1463-1473.
12. Frisch C., Hanke J., Kleineruschkamp S., Roske S., Kaaden S., Elger C.E., et al. Positive correlation between the density of neuropeptide y positive neurons in the amygdala and parameters of self-reported anxiety and depression in mesiotemporal lobe epilepsy patients. Biological Psychiatry 2009, 66:433-440.
13. Xapelli S., Agasse F., Ferreira R., Silva A.P., Malva J.O. Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide. Recent Patents on CNS Drug Discovery 2006, 1:315-324.
14. Parker R.M., Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. The European Journal of Neuroscience 1999, 11:1431-1448.
15. Gustafson E.L., Smith K.E., Durkin M.M., Walker M.W., Gerald C., Weinshank R., et al. Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system. Brain Research Molecular Brain Research 1997, 46:223-235.
16. Cannizzaro C., Tel B.C., Rose S., Zeng B.Y., Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Research Molecular Brain Research 2003, 110:169-176.
17. Kowall N.W., Beal M.F. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease. Annals of Neurology 1988, 23:105-114.
18. Alom J., Galard R., Catalan R., Castellanos J.M., Schwartz S., Tolosa E. Cerebrospinal fluid neuropeptide Y in Alzheimer's disease. European Neurology 1990, 30:207-210.
19. Koide S., Onishi H., Hashimoto H., Kai T., Yamagami S. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neuroscience Letters 1995, 198:149-151.
20. Minthon L., Edvinsson L., Gustafson L. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dementia and Geriatric Cognitive Disorders 1997, 8:232-239.
21. Nilsson C.L., Brinkmalm A., Minthon L., Blennow K., Ekman R. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Peptides 2001, 22:2105-2112.
22. Decressac M., Pain S., Chabeauti P.Y., Frangeul L., Thiriet N., Herzog H., et al. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiology of Aging 2012, 9:2125-2137.
23. Rose J.B., Crews L., Rockenstein E., Adame A., Mante M., Hersh L.B., et al. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. The Journal of Neuroscience 2009, 29:1115-1125.
24. Croce N., Dinallo V., Ricci V., Federici G., Caltagirone C., Bernardini S., et al. Neuroprotective effect of neuropeptide Y against beta-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. Neurodegenerative Diseases 2011, 8:300-309.
25. Croce N., Ciotti M.T., Gelfo F., Cortelli S., Federici G., Caltagirone C., et al. Neuropeptide Y protects rat cortical neurons against beta-amyloid toxicity and re-establishes synthesis and release of nerve growth factor. ACS Chemical Neuroscience 2012, 3:312-318.
26. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
27. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nature Reviews Molecular Cell Biology 2007, 8:101-112.
28. Malva J.O., Xapelli S., Baptista S., Valero J., Agasse F., Ferreira R., et al. Multifaces of neuropeptide Y in the brain - neuroprotection, neurogenesis and neuroinflammation. Neuropeptides 2012, 46:299-308.
29. Prediger R.D., Franco J.L., Pandolfo P., Medeiros R., Duarte F.S., Di Giunta G., et al. Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behavioural Brain Research 2007, 177:205-213.
30. Prediger R.D., Medeiros R., Pandolfo P., Duarte F.S., Passos G.F., Pesquero J.B., et al. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease. Neuroscience 2008, 151:631-643.
31. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. The Journal of Neuroscience 2007, 27:5394-5404.
32. Van Dam D., De Deyn P.P. Drug discovery in dementia: the role of rodent models. Nature Reviews Drug Discovery 2006, 5:956-970.
33. Takeda S., Sato N., Niisato K., Takeuchi D., Kurinami H., Shinohara M., et al. Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain Research 2009, 1280:137-147.
34. Passos G.F., Figueiredo C.P., Prediger R.D., Pandolfo P., Duarte F.S., Medeiros R., et al. Role of the macrophage inflammatory protein-1{alpha}/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by {beta}-amyloid peptide. The American Journal of Pathology 2009, 175:1586-1597.
35. Figueiredo C.P., Bicca M.A., Latini A., Prediger R.D., Medeiros R., Calixto J.B. Folic acid plus α-tocopherol mitigates amyloid-β-induced neurotoxicity through modulation of mitochondrial complexes activity. Journal of Alzheimers Disease 2011, 24:61-75.
36. Santos D.B., Peres K.C., Ribeiro R.P., Colle D., dos Santos A.A., Moreira E.L., et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice. Experimental Neurology 2012, 233:767-775.
37. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biology & Medicine 1997, 23:134-147.
38. Decressac M., Prestoz L., Veran J., Cantereau A., Jaber M., Gaillard A. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiology of Disease 2009, 34:441-449.
39. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. British Journal of Pharmacology and Chemotherapy 1957, 12:12-15.
40. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Research 1996, 706:181-193.
41. Bacchi F., Mathe A.A., Jimenez P., Stasi L., Arban R., Gerrard P., et al. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 2006, 27:3202-3207.
42. Pamplona F.A., Pandolfo P., Duarte F.S., Takahashi R.N., Prediger R.D. Altered emotionality leads to increased pain tolerance in amyloid beta (Abeta1-40) peptide-treated mice. Behavioural Brain Research 2010, 212:96-102.
43. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
44. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
45. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacology, Biochemistry, and Behavior 1994, 49:171-176.
46. Murai T., Okuda S., Tanaka T., Ohta H. Characteristics of object location memory in mice: behavioral and pharmacological studies. Physiology & Behavior 2007, 90:116-124.
47. Assini F.L., Duzzioni M., Takahashi R.N. Object location memory in mice: pharmacological validation and further evidence of hippocampal CA1 participation. Behavioural Brain Research 2009, 204:206-211.
48. Moreira E.L., de Oliveira J., Nunes J.C., Santos D.B., Nunes F.C., Vieira D.S., et al. Age-related cognitive decline in hypercholesterolemic LDL receptor knockout mice (LDLr-/-): evidence of antioxidant imbalance and increased acetylcholinesterase activity in the prefrontal cortex. Journal of Alzheimer's Disease 2012, 32:495-511.
49. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 1979, 95:351-358.
50. Ellman G.L. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 1959, 82:70-77.
51. Carlberg I., Mannervik B. Glutathione reductase. Methods in Enzymology 1985, 113:484-490.
52. Wendel A. Glutathione peroxidase. Methods in Enzymology 1981, 77:325-333.
53. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
54. Dringen R., Hirrlinger J. Glutathione pathways in the brain. Biological Chemistry 2003, 384:505-516.
55. Martel J.C., Alagar R., Robitaille Y., Quirion R. Neuropeptide Y receptor binding sites in human brain. Possible alteration in Alzheimer's disease. Brain Research 1990, 519:228-235.
56. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
57. Flood J.F., Baker M.L., Hernandez E.N., Morley J.E. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Research 1989, 503:73-82.
58. Silva A.P., Pinheiro P.S., Carvalho A.P., Carvalho C.M., Jakobsen B., Zimmer J., et al. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB Journal 2003, 17:1118-1120.
59. Silva A.P., Xapelli S., Grouzmann E., Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Current Drug Targets CNS and Neurological Disorders 2005, 4:331-347.
60. Smiałowska M., Domin H., Zieba B., Koźniewska E., Michalik R., Piotrowski P., et al. Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 2009, 43:235-249.
61. Piccinni A., Origlia N., Veltri A., Vizzaccaro C., Marazziti D., Vanelli F., et al. Neurodegeneration, beta-amyloid and mood disorders: state of the art and future perspectives. International Journal of Geriatric Psychiatry 2012, 10.1002/gps.3879.
62. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
63. Sun X., Steffens D.C., Au R., Folstein M., Summergrad P., Yee J., et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease. Archives of General Psychiatry 2008, 65:542-550.
64. Urani A., Romieu P., Roman F.J., Maurice T. Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice. Behavioural Brain Research 2002, 134:239-247.
65. Stogner K.A., Holmes P.V. Neuropeptide Y exerts antidepressant-like effects in the forced swim test in rats. European Journal of Pharmacology 2000, 387:R9-R10.
66. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
67. Song C., Earley B., Leonard B.E. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain, Behavior, and Immunity 1996, 10:1-16.
68. Jimenez-Vasquez P.A., Mathe A.A., Thomas J.D., Riley E.P., Ehlers C.L. Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Research Developmental Brain Research 2001, 131:149-152.
69. Caberlotto L., Fuxe K., Overstreet D.H., Gerrard P., Hurd Y.L. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Research Molecular Brain Research 1998, 59:58-65.
70. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends in Molecular Medicine 2001, 7:548-554.
71. Lyras L., Cairns N.J., Jenner A., Jenner P., Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. Journal of Neurochemistry 1997, 68:2061-2069.
72. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994, 77:817-827.
73. Ono K., Hamaguchi T., Naiki H., Yamada M. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochimica et Biophysica Acta 2006, 1762:575-586.
74. Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995, 45:1594-1601.
75. Woltjer R.L., Nghiem W., Maezawa I., Milatovic D., Vaisar T., Montine K.S., et al. Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. Journal of Neurochemistry 2005, 93:1047-1056.